Citigroup’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-16,422
| Closed | -$1.67M | – | 5841 |
|
|
2023
Q2 | $1.67M | Buy |
16,422
+8,415
| +105% | +$796K | ﹤0.01% | 2379 |
|
|
2023
Q1 | $728K | Buy |
8,007
+1,259
| +19% | +$73.9K | ﹤0.01% | 2822 |
|
|
2022
Q4 | $256K | Sell |
6,748
-3,677
| -35% | -$127K | ﹤0.01% | 3597 |
|
|
2022
Q3 | $262K | Sell |
10,425
-1,469
| -12% | -$40.7K | ﹤0.01% | 3639 |
|
|
2022
Q2 | $361K | Buy |
11,894
+3,432
| +41% | +$102K | ﹤0.01% | 3460 |
|
|
2022
Q1 | $278K | Sell |
8,462
-3,175
| -27% | -$94.2K | ﹤0.01% | 3888 |
|
|
2021
Q4 | $307K | Sell |
11,637
-15,509
| -57% | -$1.2M | ﹤0.01% | 4101 |
|
|
2021
Q3 | $2.73M | Buy |
27,146
+8,403
| +45% | +$985K | ﹤0.01% | 2292 |
|
|
2021
Q2 | $2.65M | Sell |
18,743
-337
| -2% | -$38.1K | ﹤0.01% | 2431 |
|
|
2021
Q1 | $1.9M | Buy |
19,080
+3,231
| +20% | +$377K | ﹤0.01% | 2526 |
|
|
2020
Q4 | $1.96M | Sell |
15,849
-680
| -4% | -$89.4K | ﹤0.01% | 2877 |
|
|
2020
Q3 | $1.61M | Sell |
16,529
-8,915
| -35% | -$1.11M | ﹤0.01% | 2851 |
|
|
2020
Q2 | $3.97M | Buy |
25,444
+1,991
| +8% | +$303K | ﹤0.01% | 2080 |
|
|
2020
Q1 | $3.38M | Buy |
23,453
+3,701
| +19% | +$715K | ﹤0.01% | 2011 |
|
|
2019
Q4 | $4.04M | Sell |
19,752
-580
| -3% | -$106K | ﹤0.01% | 2221 |
|
|
2019
Q3 | $1.63M | Buy |
20,332
+4,478
| +28% | +$380K | ﹤0.01% | 3091 |
|
|
2019
Q2 | $1.5M | Buy |
15,854
+5,085
| +47% | +$439K | ﹤0.01% | 3170 |
|
|
2019
Q1 | $921K | Buy |
10,769
+2,141
| +25% | +$178K | ﹤0.01% | 3498 |
|
|
2018
Q4 | $484K | Buy |
8,628
+797
| +10% | +$48.7K | ﹤0.01% | 4155 |
|
|
2018
Q3 | $640K | Buy |
7,831
+6,508
| +492% | +$459K | ﹤0.01% | 3991 |
|
|
2018
Q2 | $46K | Sell |
1,323
-1,227
| -48% | -$37.4K | ﹤0.01% | 6360 |
|
|
2018
Q1 | $52K | Buy |
2,550
+1,329
| +109% | +$34.2K | ﹤0.01% | 6142 |
|
|
2017
Q4 | $35K | Buy |
1,221
+181
| +17% | +$5.05K | ﹤0.01% | 6419 |
|
|
2017
Q3 | $32K | Buy |
1,040
+949
| +1,043% | +$28.5K | ﹤0.01% | 6222 |
|
|
2017
Q2 | $3K | Sell |
91
-668
| -88% | -$16.4K | ﹤0.01% | 6920 |
|
|
2017
Q1 | $17K | Sell |
759
-4,962
| -87% | -$123K | ﹤0.01% | 6341 |
|
|
2016
Q4 | $125K | Buy |
5,721
+5,255
| +1,128% | +$133K | ﹤0.01% | 5635 |
|
|
2016
Q3 | $12K | Sell |
466
-106
| -19% | -$2.1K | ﹤0.01% | 6475 |
|
|
2016
Q2 | $11K | Buy |
+572
| New | +$11.1K | ﹤0.01% | 6514 |
|
Other funds holding RETA
Citigroup's RETA Position: Q3 2023 in Review
Citigroup sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 16,422 shares — an estimated $1.67M sold.
Citigroup first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $4.04M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Citigroup reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Citigroup sold 16,422 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.67M.
- Citigroup first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- Citigroup's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.04M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Citigroup's 13F filing for Q3 2023, filed 9 Nov 2023.